CCDC69 Inhibitors
Inhibitors of CCDC69 encompass a variety of chemical compounds that indirectly reduce the functional activity of the protein through diverse cellular and molecular mechanisms. For instance, certain inhibitors target key signaling pathways such as mTOR, PI3K/AKT, MAPK/ERK, p38 MAPK, and JNK, which are crucial for cell growth, proliferation, survival, and stress response. Since CCDC69 is potentially implicated in these pathways, the dampening of these signals by specific inhibitors might lead to a reduction in CCDC69's activity. Furthermore, some inhibitors act by disturbing cellular homeostasis, such as disrupting calcium levels or energy production, which could indirectly affect the function of CCDC69 if it is reliant on these cellular conditions. Additionally, inhibitors that affect gene expression and protein synthesis, such as those impacting histone acetylation or blocking translational elongation, could also modulate CCDC69 levels and its activity by altering the cellular protein landscape.
Moreover, certain inhibitors interfere with the cellular machinery directly involved in the protein's life cycle or its regulatory networks. Proteasome inhibitors, for example, could lead to an accumulation of proteins within the cell, potentially affecting CCDC69 activity by altering its turnover rate or by inducing cellular stress responses that may downregulate its function. DNA-damaging agents also play a role by inducing genotoxic stress, possibly leading to altered cell cycle dynamics or activation of DNA repair pathways that might indirectly impact CCDC69.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
As an mTOR inhibitor, Rapamycin suppresses cell growth and proliferation. Since CCDC69 may be implicated in cell cycle regulation, the inhibition of mTOR could reduce CCDC69 function by limiting cellular conditions necessary for its activity. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Histone deacetylase inhibitor that alters chromatin structure and gene expression. By modifying the expression of genes that regulate CCDC69, Trichostatin A could indirectly limit its functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that disrupts the PI3K/AKT pathway, leading to inhibition of cell survival and growth signals. Since CCDC69 might be linked to these pathways through its cellular roles, LY 294002 could reduce CCDC69 function indirectly. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
MEK inhibitor that prevents the activation of the MAPK/ERK pathway. CCDC69, if related to this pathway, would have its function indirectly inhibited due to the dampening of downstream signaling cascades. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Another MEK inhibitor, similar to U0126, which could lead to decreased functional activity of CCDC69 by inhibiting the MAPK/ERK pathway and its related signaling events. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor, which could reduce the activity of CCDC69 by inhibiting stress-related signaling pathways that might regulate CCDC69 function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibitor of the JNK pathway, potentially leading to decreased CCDC69 activity by altering stress and apoptosis signaling mechanisms that CCDC69 may be involved in. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor that can affect protein degradation pathways. By altering the degradation profile of cellular proteins, Bortezomib might reduce the functional activity of CCDC69 if it is regulated by proteasomal degradation. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
SERCA pump inhibitor that disrupts calcium homeostasis. Since calcium signaling is essential for numerous cellular processes, Thapsigargin could indirectly affect CCDC69 function if it is involved in calcium-dependent pathways. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
Glycolysis inhibitor that can lead to energy depletion within the cell. If CCDC69 activity is dependent on cellular energy levels, this compound could potentially decrease its function. | ||||||